临床药理学在全球药物开发多样性与包容性中的作用:当前实践与行业视角白皮书
本文为IQ联盟多样性与包容性工作组的白皮书,评估FDA 2022年多样性计划指南草案在临床药理学领域的实施情况。文章描述行业当前实践,强调定量药理学工具可用于支持多区域临床试验中代表性不足人群的纳入,并提出整合年龄、性别、种族和合并症等人口学特征的战略与技术建议。
要点
- 定量药理学工具可支持全球药物开发中多样人群的纳入。
- 战略建议旨在将人口学特征整合到多区域III期注册研究中。
核心结论
- 行业应利用定量药理学工具在注册研究中纳入多样化人群,使药物标签适用于目标患者群体而非依赖上市后要求。
研究设计与样本
- IQ联盟多样性与包容性工作组基于调查评估FDA指南草案实施情况的白皮书。
主要发现
- 文章描述了行业当前实践,并强调定量药理学工具可支持多区域临床试验中多样化人群的纳入。
关键数值与推荐
- 提出整合年龄、性别、种族和合并症等人口学特征到多区域III期注册研究的战略与技术建议。
临床怎么用
- 临床药理学可应用定量药理学工具支持全球药物开发中多样人群的纳入。
局限性
- 全球药物开发中面临可能限制注册试验纳入更广泛多样化人群的挑战。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The 2022 United States Food and Drug Administration (US FDA) draft guidance on diversity plan (DP), which will be implemented through the Diversity Action Plans by December 2025, under the 21st Century Cures Act, marks a pivotal effort by the FDA to ensure that registrational studies adequately reflect the target patient populations based on diversity in demographics and baseline characteristics. This white paper represents the culminated efforts of the International Consortium of Quality and Innovation (IQ) Diversity and Inclusion (D&I) Working Group (WG) to assess the implementation of the draft FDA guidance by members of the IQ consortium in the discipline of clinical pharmacology (CP). This article describes current practices in the industry and emphasizes the tools and techniques of quantitative pharmacology that can be applied to support the inclusion of a diverse population during global drug development, to support diversity and inclusion of underrepresented patient populations, in multiregional clinical trials (MRCTs). It outlines strategic and technical recommendations to integrate demographics, including age, sex/gender, race/ethnicity, and comorbidities, in multiregional phase III registrational studies, through the application of quantitative pharmacology. Finally, this article discusses the challenges faced during global drug development, which may otherwise limit the enrollment of a broader, potentially diverse population in registrational trials. Based on the outcomes of the IQ survey that provided the current awareness of diversity planning, it is envisioned that in the future, industry efforts in the inclusion of previously underrepresented populations during global drug development will culminate in drug labels that apply to the intended patient populations at the time of new drug application or biologics license application rather than through post-marketing requirements.
引用
- Sawant-Basak A, Urva S, Mukker JK, et al. Role of Clinical Pharmacology in Diversity and Inclusion in Global Drug Development: Current Practices and Industry Perspectives: White Paper. Clin Pharmacol Ther. 2024. PMID: 38973127. doi:10.1002/cpt.3350
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。